Business Wire: CuriRx Won National Cancer Institute’s Contract

WILMINGTON, Mass.–(BUSINESS WIRE)–CuriRx, Inc., specializing in providing drug product development services, is pleased to announce that they have been awarded a 5-year contract with the National Cancer Institute (“NCI”) under solicitation number N02CM37007-11, Contract# HHSN261201300034I, entitled “Development and Production of Parenteral Dosage Forms for Clinical Studies” on September 20^th 2013. The primary objective of this project is to develop and produce pharmaceutically acceptable parenteral dosage forms of cancer drugs for human use. The Development Therapeutics Program (DTP) of the National Cancer Institute (NCI) Division of Cancer Treatment and Diagnosis (DCTD) will provide promising new agents with activity against cancer for development and production as parenteral products.  Read more